On Sunday, July 31, 2022, the Faculty of Public Health (FPH) of the Universitas Indonesia (UI) held a webinar entitled “Health Economic Evaluation for Innovative Medicine”, the first series. This webinar is part of the 2nd International Teleconference on Technology and Policy for Supporting Implementation of the COVID-19 Recovery Plan in Southeast Asia (ITTP-COVID19). The webinar, which was held through the Zoom Webinar platform, began with remarks from the Dean of FPH UI, Prof. dr. Mondastri Korib Sudaryo, M.S, D.Sc.
The main material entitled “Cost-Effectiveness Analysis: Innovative Medicines Between Needs and Social Insurance Sustainability” was delivered directly by the Head of the Center for Health Financing and Decentralization Policy, Ministry of Health, dr. Yuli Farianti, M. Epid. In his presentation, dr. Yuli conveyed about the National Health Insurance ranging from general understanding, development, to how to control its quality. The health transformation being carried out by the Ministry of Health has an impact on JKN. Therefore, it is necessary to have an assessment of health technology which is then called Health Technology Assessment (HTA). “Development of health science and technology is fast and expensive, while economic resources are limited. That’s why we need a method to prioritize technology that is both capable and affordable,” said dr. Yuli.
Furthermore, the presentation of the material was moderated by the Professor of FPH UI, Prof. Dr. dr. Sabarinah, M.Sc. The first material on the development and challenges of HTA in Indonesia was delivered by the Chair of the Indonesian HTA Committee (INA-HTAC), Prof. Dr. dr. Budi Wiweko, Sp.OG(K), MARS. In his presentation, Prof. Budi said that the development of HTA in Indonesia requires more participation from BPJS and the health industries. Therefore, the current roadmap for HTA development is to strengthen institutionalization through increased participation of all key stakeholders in implementing HTA studies and developing various HTA models.
The second material on the practice and theory of HTA was presented by the Professor of FPH UI, Prof. Dr. drg. Mardiati Nadjib, M.S. Prof. Mardiati explained about the basics of HTA theory, why HTA is important, as well as its methods and practices. “The HTA process is actually a long and not simple process. The scheme consists of safety, efficacy, effectiveness, cost-effectiveness, and affordability. There are different stakeholders at each stage,” explained Prof. Mardiati.
In addition to the material presentation, there are also case studies with 4 (four) topics presented by experts in their fields. In this session, the speakers explained their experiences in implementing HTA in their respective fields. The four speakers were Auliya A. Suwantika, S.Si., Ph.D., Apt., from the Center for HTA at Padjadjaran University who delivered material entitled “Is COVID-19 vaccination cost-effective, affordable, and sustainable?”; Prof. Dr. Ema Kristin, M.Sc., Apt., Professor in pharmacology, Gadjah Mada University who delivered material entitled “Cost-Effectiveness Analysis in Indonesia: Published Paper”; dr. Ronald A. Hukom, Sp.PD, KHOM from Dharmais Cancer Hospital who delivered material entitled “Clinical Overview of CDK4/6 Inhibitors in HR+, HER2- Advanced Breast Cancer”; and Adrian Goh as a senior economic analyst at Novartis who delivered a material entitled “Case Study: Cost-Effectiveness Analysis of First-Line Ribociclib + Letrozole in Postmenopausal HR+, HER2- Advanced Breast Cancer”. (BK)